Potential Therapeutic Strategy in Chronic Obstructive Pulmonary Disease Using Pioglitazone-Augmented Wharton's Jelly-Derived Mesenchymal Stem Cells

Jin-Soo Park, Ph.D.1*, Hyun Kuk Kim, M.D.2*, Eun-Young Kang, M.S.1, RyeonJin Cho, M.S.1 and Yeon-Mok Oh, M.D., Ph.D.1,3,4*

1Asan Institute for Life Sciences, Seoul, 2Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Inje University Haeundae Paik Hospital, Busan, 3Department of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine, Seoul, 4Department of Pulmonary and Critical Care Medicine, Asan Medical Center, Seoul, Korea

Background: A recent study reported that mesenchymal stem cells possess potential cellular therapeutic properties for treating patients with chronic obstructive pulmonary disease, which is characterized by emphysema. We examined the potential therapeutic effect of Wharton’s jelly-derived mesenchymal stem cells (WJMSCs), following pretreatment with pioglitazone, in lung regeneration mouse emphysema models.

Methods: We used two mouse emphysema models, an elastase-induced model and a cigarette smoke-induced model. We intravenously injected WJMSCs (1×10⁴/mouse) to mice, pretreated or not, with pioglitazone for 7 days. We measured the emphysema severity by mean linear intercepts (MLI) analysis using lung histology.

Results: Pioglitazone pretreated WJMSCs (pioWJMSCs) were associated with greater lung regeneration than non-augmented WJMSCs in the two mouse emphysema models. In the elastase-induced emphysema model, the MLIs were 59.02±2.42 μm (n=6), 72.80±2.87 μm (n=6), for pioWJMSCs injected mice, and non-augmented WJMSCs injected mice, respectively (p<0.01). Both pioWJMSCs and non-augmented WJMSCs showed regenerative effects in the cigarette smoke emphysema model (MLIs were 41.25±0.98 μm [n=6] for WJMSCs and 38.97±0.61 μm [n=6] for pioWJMSCs) compared to smoking control mice (51.65±1.36 μm, n=6). The mean improvement of MLI appeared numerically better in pioWJMSCs than in non-augmented WJMSCs injected mice, but the difference did not reach the level of statistical significance (p=0.071).

Conclusion: PioWJMSCs may produce greater lung regeneration, compared to non-augmented WJMSCs, in a mouse emphysema model.

Keywords: Pioglitazone; Mesenchymal Stem Cells; Emphysema

Address for correspondence: Yeon-Mok Oh, M.D., Ph.D.
Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Korea
Phone: 82-2-3010-3136, Fax: 82-2-3010-4650 E-mail: ymoh55@amc.seoul.kr
*Jin-Soo Park and Hyun Kuk Kim contributed equally to this work
Received: May. 15, 2018 Revised: Jun. 20, 2018 Accepted: Jul. 17, 2018 Published online: Sep. 28, 2018

©It is identical to the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/).
**Introduction**

Chronic obstructive pulmonary disease (COPD) is characterized by irreversible airflow limitation associated with chronic bronchitis and emphysema, and is known as one of the leading causes of death worldwide. Although the etiology of COPD remains unclear, there is a clear relationship between smoking and chronic airway inflammation, alveolar destruction by extracellular matrix proteolysis, and ineffective repair of resident lung cells. Recent reports describe the effects of stem cell treatments on tissue regeneration in organs like the heart, brain, liver, and lungs. Several reports indicated that mesenchymal stem cells (MSCs) from bone marrow had therapeutic effects in an experimental elastase-induced emphysema model and a cigarette smoke-induced model. Other reports examined use of Wharton’s Jelly-derived mesenchymal stem cells (WJMSCs) and their potential clinical cell therapy applications in various disease models. In this study, we isolated WJMSCs and then examined the effect of WJMSCs injection on two emphysema mouse models, an elastase-induced mouse model and a cigarette smoke-induced mouse model.

Our recent research showed that pioglitazone pretreatment of adipose-derived MSCs increased the production of growth factors, and the resultant therapeutic effects, in an emphysema mouse model, compared to non-treated adipose-derived stem cells. We applied this method in an attempt to improve the efficacy of WJMSCs in two emphysema mouse models. Additionally, we sought to identify the distribution of intravenously injected WJMSCs pretreated with pioglitazone (pioWJMSCs), prior to human application.

**Materials and Methods**

1. **Cell sources and pretreatment with pioglitazone**

Following the receipt of parental consent, we obtained Wharton’s Jelly from the umbilical cord of a baby born at Asan Medical Center in Seoul, Korea. WJMSCs were isolated by the following method. After removal of blood vessels, we dissected the Wharton’s jelly, using a scalpel, into small segments. The dissected tissue segments were cultured in a 100-mm cell culture dish with minimum essential medium, alpha modification containing 10% fetal bovine serum and antibiotics in a humidified 37°C, 5% CO₂ incubator. After 1 week, the cultured tissue segments were treated with 0.05% trypsin-EDTA (Gibco Life Technologies, Grand Island, NY, USA) and then passed through a 0.45-μm cell strainer to obtain WJMSCs. For pio-WJMSCs (pioglitazone, Sigma-Aldrich, St. Louis, MO, USA), the WJMSCs culture medium was treated with 3 μmol/L pioglitazone for 1 week.

2. **Mice**

Female C57BL/6 mice, aged 7 weeks, were purchased from Orient Bio (Seongnam, Korea) and maintained under specific pathogen-free conditions in the animal facility of the Institutional Animal Care and Use Committee of Asan Medical Center.

3. **Induction of two mouse emphysema models**

As described previously, we induced an experimental elastase-induced emphysema model by intratracheal injection of 0.6 U of porcine pancreatic elastase (Sigma-Aldrich) at day 0. The mice were injected with 1×10⁶ of pioWJMSC or WJMSC by intravenous injection on day 7. The animals were killed on day 14, after which the lungs were removed and prepared for histological analysis.

As described previously, for the experimental smoke-induced emphysema model we exposed mice to cigarette smoke 5 days per week for 6 months using commercially available cigarettes that contained 8.0 mg of tar and 0.6 mg of nicotine (Camel, R. J. Reynolds Tobacco Company, Winston-Salem, NC, USA). After exposure to cigarette smoke for 6 months, the mice were injected with 1×10⁶ of pioWJMSCs or WJMSCs by intravenous injection and then killed on day 7 immediately prior to lung removal and preparation.

4. **Histology and quantification of emphysema**

Lung tissue was inflated with 0.5% low melting agarose, fixed in 4% formalin, embedded in paraffin, cut into 6-μm thickness, and stained with hematoxylin and eosin. Histological assessment of the sections was determined using the mean linear intercepts (MLI) method.

5. **Fluorescence optical imaging**

For injected pioWJMSC tracking in the lung, we performed fluorescence optical imaging analysis, as described previously. In brief, pioWJMSCs were labeled using the quantum dots (QD) (Q-Tracker 800) Cell Labeling Kit (Invitrogen, Carlsbad, CA, USA). PioWJMSCs (1×10⁶) were suspended in 200 μL of complete growth medium and labeled with 10 nM of QDs labeling solution. After 60 minutes, QD-labeled cells were washed twice with complete growth medium. We suspended 3×10⁶ QDs 800-labeled pioWJMSCs in 100 μL saline and injected into the mice through the tail vain. The mice were sacrificed after 1, 4, 24, and 72 hours and image of the lung was taken using the IVIS Spectrum Pre-clinical In vivo Imaging System (PerkinElmer, Waltham, MA, USA).
6. WJMSC tracking using human-specific Alu sequence

We suspended 3×10^5 pioWJMSCs in 100 μL saline, then injected this solution into the mice through the tail vain. The mice were sacrificed after 1, 4, 24, and 72 hours, after which the lungs were removed to extract genomic DNA using a genomic DNA extraction kit (Qiagen, Duesseldorf, Germany). To verify the number of detected lung cells, we performed a standard curve using the pioWJMSCs. A quantitative polymerase chain reaction (qPCR) was carried out as previously described^24. In brief, polymerase chain reactions (PCRs) were amplified by 40 cycles at 95°C for 15 seconds and 70°C for 1 minute using the LightCycler 480 SYBR Green I Master (Roche, Mannheim, Germany). PCR was carried out using the LightCycler 480 and software. Primer sequences were as follows: Alu, 5′-CGAGGCGGGTTGATCTGAGGT-3′ and 5′-TCTGTGGAGAGGGCTAAGGACT-3′.

7. Ethical statement

This study was approved by the institutional review board of the Asan Medical Center (approval No. 2015-0303). The receipt of parental consent was obtained.

Results

1. Increased therapeutic effects of pioWJMSCs on lung regeneration in mice with emphysema

1) Elastase-induced emphysema model

Experimental mice with emphysema are widely used to study COPD and the effects of MSCs. To evaluate the effect of pioWJMSCs, we used an elastase-induced emphysema model with intravenous injection of pioWJMSCs or WJMSCs (Figure 1A). Intratracheal injection of elastase produced severe lung destruction with MLI, an emphysema severity index, increasing from 43.55±1.9 to 92.57±4.56 μm (p<0.0001) (Figure 1B).

Figure 1. The therapeutic effects of pioglitazone-augmented Wharton’s Jelly-derived mesenchymal stem cells (pioWJMSCs) on lung regeneration in mice with elastase-induced emphysema. C57BL/6 mice were intratracheally injected with 0.6 U of elastase (Ela) at day 0 and then intravenously injected with Wharton’s Jelly-derived mesenchymal stem cells (WJMSCs) or pioWJMSCs on day 7. (A) Experiment scheme. (B) Hematoxylin and eosin (H&E) stained lung tissue sections on day 14. (-) control: no elastase; Ela: 0.6 U of elastase; Ela+WJMSC: elastase+1×10^4 WJMSC; Ela+pioWJMSC: elastase+1×10^4 pioWJMSC. Scale bars=0.5 mm. (C) Morphometric analysis of the mean linear intercept (MLI). The values represent the mean±standard error of mean (n=6). Statistically significant differences are indicated. **p<0.01, ***p<0.001, ****p<0.0001.
Therapeutic effects of stem cells in an emphysema

C). In contrast, both the pioWJMSCs and WJMSCs injection groups exhibited lung regeneration (Figure 1B, C). The mice injected with WJMSCs showed decreased MLI (72.80±2.87 μm) and the MLI of pioWJMSCs (59.02±2.42 μm) was significantly decreased, even more than the WJMSCs group (p<0.01). These results suggested that pioWJMSCs may exhibit augmented regenerative activity in an elastase-induced emphysema model.

2) Cigarette smoke-induced emphysema model

We observed similar results in the smoke-induced emphysema model (Figure 2A–C). The smoking (SM) group showed lung destruction with MLI increases from 35.43±0.8 to 51.65±1.36 μm (p<0.0001) (Figure 2B, C). Both the pio-WJMSCs and WJMSCs injected groups showed significantly decreased MLI (WJMSCs 41.25±0.98 μm, pioWJMSCs 38.97±0.61 μm; p<0.001) compared to the SM group that was not treated, but the difference did not rise to the level of statistical significance (p=0.071).

2. Tracking of pioWJMSCs after intravenous injection into the mice

1) QDs-labeled fluorescence image

To track the distribution of intravenously injected pioWJMSCs in the lung, the pioWJMSCs were labeled with QDs. QDs-labeled pioWJMSCs were intravenously injected into the mice, and the fluorescence levels in the lung were analyzed using an optical imaging system at 1, 4, 24, and 72 hours after injection. The fluorescent signal was detected in the lung up to 4 hours (Figure 3A) and gradually decreased as time passed (Figure 3B). In the control group, the fluorescent signal was undetectable in the lungs at all times. After 72 hours postinjection, we detected no fluorescent signals in the pioWJMSCs group.

2) Tracking using a human-specific Alu sequence

To quantify the relative amount of intravenously injected pioWJMSCs, we performed qPCR with a human-specific Alu sequence using extracted genomic DNA in pioWJMSCs injected, and non-injected, mice lungs. For analysis using human Alu-specific sequences qPCR data, the regression r² value curve was determined by 10 ng of genomic DNA from

Figure 2. The therapeutic effects of pioglitazone-augmented Wharton’s Jelly-derived mesenchymal stem cells (pioWJMSCs) on lung regeneration in mice with smoke-induced emphysema. C57BL/6 mice were exposed to cigarette smoke (SM) for 6 months and then intravenously injected with Wharton’s Jelly-derived mesenchymal stem cells (WJMSCs) or pioWJMSCs. (A) Experiment scheme. (B) Hematoxylin and eosin (H&E) stained lung tissue sections after 7 days of injection. (−) control: no smoke; SM: smoke only; SM+WJMSC: smoke+1×10⁴ WJMSC; SM+pioWJMSC: smoke+1×10⁴ pioWJMSC. Scale bars=0.5 mm. (C) Morphometric analysis of the mean linear intercept (MLI). The values represent the mean±standard error of mean (n=6). Statistically significant differences are indicated. ***p<0.001, ****p<0.0001. ns, not significant.
Figure 3. Tracking of pioglitazone-augmented Wharton's Jelly-derived mesenchymal stem cells (pioWJMSCs) after intravenous injection in the lung. (A) The fluorescence images of the lung from (–) control mice or quantum dots (QDs) labeled pioWJMSCs-intravenously injected mice at 1, 4, 24, and 72 hours. Representative images are shown (n=3). (B) Radiant efficiency of the lung from (–) control mice or QDs labeled pioWJMSCs-intravenously injected mice at 1, 4, 24, and 72 hours. Statistically significant differences are indicated. ***p<0.001.

Figure 4. The quantification of the amount of intravenously injected pioglitazone-augmented Wharton's Jelly-derived mesenchymal stem cells (pioWJMSCs) in the lung. (A) Standard curve to evaluate the determination of pioWJMSCs in the lung. (B) The amount of pioWJMSCs in the lung from pioWJMSCs-injected mice or control mice was calculated based on panel A. The values represent the mean±standard error of mean (n=3). Statistically significant differences are indicated. **p<0.01.
Therapeutic effects of stem cells in an emphysema

WJMSCs are a source of MSCs for therapeutic applications. The isolation efficiency of WJMSCs was greater than that of bone marrow or adipose tissue. WJMSCs also exhibit higher proliferative capacity, abundant production of growth factors, and lack of immunogenicity.

In COPD, the regeneration mechanisms of stem cells are not clearly identified; however, several studies have achieved regeneration secondary to the paracrine effects of MSCs, and growth factors such as vascular endothelial growth factor-2 enhance stem cell regeneration in canine emphysema models.

WJMSCs are relatively undifferentiated cells, compared to stem cells derived from adipose tissue or bone marrow. WJMSCs also express CD29, CD44, CD73, CD90, and CD92, similar to bone marrow or other tissue-derived mesenchymal stem cells, but the hematopoietic stem cell markers CD34, CD45, and histocompatibility antigen CD14, CD31, and CD33 are not expressed. These features may facilitate the use of WJMSCs as cell therapy agents. In this study, we attempted to enhance the efficacy of WJMSCs using pioglitazone in an emphysema mouse model.

For future clinical trials of WJMSCs in COPD patients, we need to identify the distribution of intravenously injected WJMSCs. To accomplish this, we performed fluorescence optical imaging and human Alu-specific sequence qPCR for WJMSCs tracking in the lung. These data suggest potential clinical therapeutic effects of WJMSCs in COPD.

In conclusion, the results of this study agree with previous findings regarding the regenerative effects of MSCs. WJMSCs were more potent, and may serve as a basis for clinical trials with patients in the near future.

Authors’ Contributions

Conceptualization: Oh YM. Methodology: Park JS, Kim HK. Formal analysis: Park JS, Kim HK. Data curation: Park JS, Kang EY, Cho R. Validation: Park JS, Kim HK. Investigation: Park JS, Kang EY, Cho R. Writing - original draft preparation: Park JS, Kang EY, Cho R. Writing - review and editing: Oh YM. Approval of final manuscript: all authors.

Conflicts of Interest

No potential conflicts of interest relevant to this article are reported.

Acknowledgments

The authors thank the members of the Asan Medical Center animal facility and the imaging core lab for their technical expertise. This study was supported by grants from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (no. HI16C2187).

References

1. Murphy TF, Sethi S. Chronic obstructive pulmonary disease: role of bacteria and guide to antibacterial selection in the older patient. Drugs Aging 2002;19:761-75.
2. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelemeier C, An-
zueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347-65.

3. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet 2004;364:613-20.

4. Agusti AG, Nogueira A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003;21:347-60.

5. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004;364:709-21.

6. MacNee W, Goolaerts A, Howard JP, Lee JW. Mesenchymal stem cells repair cigarette smoke-induced emphysema in rats. Am J Physiol Lung Cell Mol Physiol 2011;301:L255-66.

7. Zhu Y, Chen X, Yang X, Ei-Hashash A. Stem cells in lung regeneration: current applications and future promise. J Cell Physiol 2015;230:520-6.

8. Zhao DC, Lei JX, Chen R, Yu WH, Zhang XM, Li SN, et al. Bone marrow-derived mesenchymal stem cells protect against experimental liver fibrosis in rats. World J Gastroenterol 2005;11:3431-40.

9. Longhini-Dos-Santos N, Barbosa-de-Oliveira VA, Kozma RH, Faria CA, Stessuk T, Frei F, et al. Cell therapy with bone marrow mononuclear cells in elastase-induced pulmonary emphysema. Stem Cell Rev 2013;9:210-8.

10. Zhu Y, Chen X, Yang X, Ei-Hashash A. Stem cells in lung repair and regeneration: current applications and future promise. J Cell Physiol 2018;233:6414-24.

11. Mathay MA, Goolaerts A, Howard JP, Lee JW. Mesenchymal stem cells for acute lung injury: preclinical evidence. Crit Care Med 2010;38(10 Suppl):S569-73.

12. Longhini-Dos-Santos N, Barbosa-de-Oliveira VA, Kozma RH, Faria CA, Stessuk T, Frei F, et al. Cell therapy with bone marrow mononuclear cells in elastase-induced pulmonary emphysema. Stem Cell Rev 2013;9:210-8.

13. Katsa AM, Ohkouchi S, Xin H, Kanehira M, Sun R, Nukiwa T, et al. Paracrine factors of multipotent stromal cells ameliorate lung injury in an elastase-induced emphysema model. Mol Ther 2011;19:196-203.

14. Kim DW, Staples M, Shinozuka K, Pantcheva P, Kang SD, Borlongan CV. Wharton’s jelly-derived mesenchymal stem cells: phenotypic characterization and optimizing their therapeutic potential for clinical applications. Int J Mol Sci 2013;14:11692-712.

15. Hammam OA, Elkhaffif N, Attia YM, Mansour MT, Elmazar MM, Abdelsalam RM, et al. Wharton’s jelly-derived mesenchymal stem cells combined with praziquantel as a potential therapy for Schistosoma mansoni-induced liver fibrosis. Sci Rep 2016;6:21005.

16. Kim DW, Staples M, Shinozuka K, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003;21:347-60.

17. Amable PR, Teixeira MV, Caria RB, Granjeiro JM, Borojevic R. Protein synthesis and secretion in human mesenchymal cells derived from bone marrow, adipose tissue and Wharton’s jelly. Stem Cell Rev 2014;10:55-63.

18. Yoon JH, Roh EY, Shin S, Jung NH, Song EY, Chang JY, et al. Comparison of explant-derived and enzymatic digestion-derived MSCs and the growth factors from Wharton’s jelly. Biomed Res Int 2013;2013:428726.

19. Weiss ML, Anderson C, Medicetty S, Seshareddy KB, Weiss RJ, VanderWerff I, et al. Immune properties of human umbilical cord Wharton’s jelly-derived cells. Stem Cells 2008;26:2865-
Therapeutic effects of stem cells in an emphysema

32. Jyothi Prasanna S, Sowmya Jahnavi V. Wharton’s jelly mesenchymal stem cells as off-the-shelf cellular therapeutics: a closer look into their regenerative and immunomodulatory properties. Open Tissue Eng Regen Med J 2011;4:28-38.

33. Hackett TL, Knight DA, Sin DD. Potential role of stem cells in management of COPD. Int J Chron Obstruct Pulmon Dis 2010;5:81-8.

34. Yoshida H, Kitaichi T, Urata M, Kurobe H, Kanbara T, Motoki T, et al. Syngeneic bone marrow mononuclear cells improve pulmonary arterial hypertension through vascular endothelial growth factor upregulation. Ann Thorac Surg 2009;88:118-24.

35. Murphy MB, Moncivais K, Caplan AI. Mesenchymal stem cells: environmentally responsive therapeutics for regenerative medicine. Exp Mol Med 2013;45:e54.

36. Muyal JP, Muyal V, Kotnala S, Kumar D, Bhardwaj H. Therapeutic potential of growth factors in pulmonary emphysema-tous condition. Lung 2013;191:147-63.

37. Guan XJ, Song L, Han FF, Cui ZL, Chen X, Guo XJ, et al. Mesenchymal stem cells protect cigarette smoke-damaged lung and pulmonary function partly via VEGF-VEGF receptors. J Cell Biochem 2013;114:323-35.

38. Morino S, Nakamura T, Toba T, Takahashi M, Kusihibi T, Tabata Y, et al. Fibroblast growth factor-2 induces recovery of pulmonary blood flow in canine emphysema models. Chest 2005;128:920-6.

39. Stenderup K, Justesen J, Clausen C, Kassem M. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone 2003;33:919-26.

40. Romanov YA, Svititsitskaya VA, Smirnov VN. Searching for alternative sources of postnatal human mesenchymal stem cells: candidate MSC-like cells from umbilical cord. Stem Cells 2003;21:105-10.

41. Karahuseyinoglu S, Cinar O, Kilic E, Kara F, Akay GG, Demiralp DO, et al. Biology of stem cells in human umbilical cord stroma: in situ and in vitro surveys. Stem Cells 2007;25:319-31.

42. Carlin R, Davis D, Weiss M, Schulz B, Troyer D. Expression of early transcription factors Oct-4, Sox-2 and Nanog by porcine umbilical cord (PUC) matrix cells. Reprod Biol Endocrinol 2006:48.

43. Choudhery MS, Badowski M, Muise A, Harris DT. Comparison of human mesenchymal stem cells derived from adipose and cord tissue. Cytotherapy 2013;15:330-43.

44. Wang HS, Hung SC, Peng ST, Huang CC, Wei HM, Guo YL, et al. Mesenchymal stem cells in the Wharton’s jelly of the human umbilical cord. Stem Cells 2004;22:1330-7.

45. Yukawa H, Mizufune S, Mamori C, Kagami Y, Oishi K, Kaji N, et al. Quantum dots for labeling adipose tissue-derived stem cells. Cell Transplant 2009;18:591-9.

46. Yukawa H, Watanabe M, Kaji N, Okamoto Y, Tokeshi M, Miymoto Y, et al. Monitoring transplanted adipose tissue-derived stem cells combined with heparin in the liver by fluorescence imaging using quantum dots. Biomaterials 2012;33:2177-86.

47. Batzer MA, Deininger PL. Alu repeats and human genomic diversity. Nat Rev Genet 2002;3:370-9.

48. Nicklas JA, Buel E. Development of an Alu-based, real-time PCR method for quantitation of human DNA in forensic samples. J Forensic Sci 2003;48:936-44.

49. Batzer MA, Gudi VA, Mena JC, Foltz DW, Herrera RJ, Deininger PL. Amplification dynamics of human-specific (HS) Alu family members. Nucleic Acids Res 1991;19:3619-23.